Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Bionime's interest expense for the
three
months ended in Dec. 2025 was NT$ -17 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-65 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Bionime's Operating Income for the
three
months ended in Dec. 2025 was NT$ -98 Mil. Bionime's Interest Expense for the
three
months ended in Dec. 2025 was NT$ -17 Mil.
Bionime did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Bionime (TPE:4737) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Bionime's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as
Bionime did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Bionime Interest Expense Historical Data
* Premium members only.
The historical data trend for Bionime's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime (TPE:4737) has a Interest Expense of NT$-65 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Bionime and its competitors.
Is Bionime's Interest Expense too high?
Bionime's current Interest Expense is NT$-65 Mil. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Interest Expense compare to ISRG and BDX?
Bionime's Interest Expense of NT$-65 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Bionime and its competitors. Bionime's current Interest Expense is NT$-65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.80, compared to a current price of NT$57.90 — trading 1.5% below its estimated fair value. The current Interest Expense is NT$-65 Mil. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Bionime (TPE:4737), the current Interest Expense is NT$-65 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionime (TPE:4737) Overvalued in 2026?
Based on GuruFocus' analysis, Bionime stock appears to be undervalued.
The current stock price of NT$57.90 is trading 1.5% below its estimated GF Value™ of NT$58.80.
GuruFocus considers Bionime to be Fairly Valued.
Key valuation signals for TPE:4737:
Interest Expense: NT$-65 Mil
GF Value™: NT$58.80 vs. price of NT$57.90 (1.5% below fair value)
No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score
Get the complete analysis for TPE:4737
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4737 has been successfully added to your 
